Adriana Virgínia Barros Faiçal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Adriana Virgínia Barros Faiçal has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Edna Lúcia Souza
Universidade Federal da Bahia
4 shared publications - Regina Terse-Ramos
Universidade Federal da Bahia, Brazil
4 shared publications - Angelina Xavier Acosta
Universidade Federal da Bahia, Brazil
2 shared publications - Fernanda Fontenelle
Universidade Federal da Bahia
2 shared publications - Isadora Cristina de Siqueira
Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Fiocruz Bahia, Salvador 40296-710, Brazil
2 shared publications - Juliana Cana Brazil Costa
Universidade Federal da Bahia
2 shared publications
Latest Publications
- Open Access
- 2 January 2026
- Published by Jornal de Assistencia Farmaceutica e Farmacoeconomia in JORNAL DE ASSISTÊNCIA FARMACÊUTICA E FARMACOECONOMIA
- Vol. 11 (1)
Treatment adherence in individuals with cystic fibrosis: An Observational Study
Introduction: Low treatment adherence is a complex issue frequently observed in cystic fibrosis (CF) patients. Objective: To evaluate the self-reported treatment adherence rate and the rate determined based on pharmacy medication dispensation records in individuals with CF, and to investigate the association between treatment adherence and sociodemographic and clinical variables. Methods: Cross-sectional study with a consecutive sample was conducted in a CF referral center in the Northeast of Brazil. Using two methods: (1) The Morisky-Green test measured the self-reported treatment adherence for pancreatin, dornase alfa, and inhaled tobramycin; (2) dispensation records of prescribed drugs. A medication usage percentage ≥ 80% was classified as good treatment adherence. Prevalence ratios were used to assess associations between good treatment adherence and studied variables. Results: Forty-two individuals were included, 55.8% female, median age 7.3 years. Self-reported good treatment adherence for the use of pancreatin, dornase alfa, and inhaled tobramycin were 65.8%, 50.0%, and 44.4% of the participants, respectively. According to pharmacy records, the percentages of good treatment adherence were 71.4%, 66.7%, and 52.6% for the use of dornase alfa, tobramycin, and pancreatin, respectively. When comparing the methods, the agreement in treatment adherence rates for medication use ranged from 64.0% to 85.7%. Conclusion: Treatment adherence was low and varied by medication and methodology. Good adherence was mainly associated with younger age and the educational level.
- 2 January 2026
- Published by Jornal de Assistencia Farmaceutica e Farmacoeconomia in JORNAL DE ASSISTÊNCIA FARMACÊUTICA E FARMACOECONOMIA
- Vol. 11 (1)
Open AccessTreatment adherence in individuals with cystic fibrosis: An Observational Study
Introduction: Low treatment adherence is a complex issue frequently observed in cystic fibrosis (CF) patients. Objective: To evaluate the self-reported treatment adherence rate and the rate determined based on pharmacy medication dispensation records in individuals with CF, and to investigate the association between treatment adherence and sociodemographic and clinical variables. Methods: Cross-sectional study with a consecutive sample was conducted in a CF referral center in the Northeast of Brazil. Using two methods: (1) The Morisky-Green test measured the self-reported treatment adherence for pancreatin, dornase alfa, and inhaled tobramycin; (2) dispensation records of prescribed drugs. A medication usage percentage ≥ 80% was classified as good treatment adherence. Prevalence ratios were used to assess associations between good treatment adherence and studied variables. Results: Forty-two individuals were included, 55.8% female, median age 7.3 years. Self-reported good treatment adherence for the use of pancreatin, dornase alfa, and inhaled tobramycin were 65.8%, 50.0%, and 44.4% of the participants, respectively. According to pharmacy records, the percentages of good treatment adherence were 71.4%, 66.7%, and 52.6% for the use of dornase alfa, tobramycin, and pancreatin, respectively. When comparing the methods, the agreement in treatment adherence rates for medication use ranged from 64.0% to 85.7%. Conclusion: Treatment adherence was low and varied by medication and methodology. Good adherence was mainly associated with younger age and the educational level.
- Open Access
- 2 January 2026
- Published by Jornal de Assistencia Farmaceutica e Farmacoeconomia in JORNAL DE ASSISTÊNCIA FARMACÊUTICA E FARMACOECONOMIA
- Vol. 11 (1)
Treatment adherence in individuals with cystic fibrosis: An Observational Study
Introduction: Low treatment adherence is a complex issue frequently observed in cystic fibrosis (CF) patients. Objective: To evaluate the self-reported treatment adherence rate and the rate determined based on pharmacy medication dispensation records in individuals with CF, and to investigate the association between treatment adherence and sociodemographic and clinical variables. Methods: Cross-sectional study with a consecutive sample was conducted in a CF referral center in the Northeast of Brazil. Using two methods: (1) The Morisky-Green test measured the self-reported treatment adherence for pancreatin, dornase alfa, and inhaled tobramycin; (2) dispensation records of prescribed drugs. A medication usage percentage ≥ 80% was classified as good treatment adherence. Prevalence ratios were used to assess associations between good treatment adherence and studied variables. Results: Forty-two individuals were included, 55.8% female, median age 7.3 years. Self-reported good treatment adherence for the use of pancreatin, dornase alfa, and inhaled tobramycin were 65.8%, 50.0%, and 44.4% of the participants, respectively. According to pharmacy records, the percentages of good treatment adherence were 71.4%, 66.7%, and 52.6% for the use of dornase alfa, tobramycin, and pancreatin, respectively. When comparing the methods, the agreement in treatment adherence rates for medication use ranged from 64.0% to 85.7%. Conclusion: Treatment adherence was low and varied by medication and methodology. Good adherence was mainly associated with younger age and the educational level.
- 2 January 2026
- Published by Jornal de Assistencia Farmaceutica e Farmacoeconomia in JORNAL DE ASSISTÊNCIA FARMACÊUTICA E FARMACOECONOMIA
- Vol. 11 (1)
Open AccessTreatment adherence in individuals with cystic fibrosis: An Observational Study
Introduction: Low treatment adherence is a complex issue frequently observed in cystic fibrosis (CF) patients. Objective: To evaluate the self-reported treatment adherence rate and the rate determined based on pharmacy medication dispensation records in individuals with CF, and to investigate the association between treatment adherence and sociodemographic and clinical variables. Methods: Cross-sectional study with a consecutive sample was conducted in a CF referral center in the Northeast of Brazil. Using two methods: (1) The Morisky-Green test measured the self-reported treatment adherence for pancreatin, dornase alfa, and inhaled tobramycin; (2) dispensation records of prescribed drugs. A medication usage percentage ≥ 80% was classified as good treatment adherence. Prevalence ratios were used to assess associations between good treatment adherence and studied variables. Results: Forty-two individuals were included, 55.8% female, median age 7.3 years. Self-reported good treatment adherence for the use of pancreatin, dornase alfa, and inhaled tobramycin were 65.8%, 50.0%, and 44.4% of the participants, respectively. According to pharmacy records, the percentages of good treatment adherence were 71.4%, 66.7%, and 52.6% for the use of dornase alfa, tobramycin, and pancreatin, respectively. When comparing the methods, the agreement in treatment adherence rates for medication use ranged from 64.0% to 85.7%. Conclusion: Treatment adherence was low and varied by medication and methodology. Good adherence was mainly associated with younger age and the educational level.
- Open Access
- 1 January 2024
- Published by FapUNIFESP (SciELO) in Revista Paulista de Pediatria
- Vol. 42, e2024111
Telehealth for children and adolescents with chronic pulmonary disease: systematic review
To revise the impact of telehealth on the quality of life, reduction in pulmonary exacerbations, number of days using antibiotics, adherence to treatment, pulmonary function, emergency visits, hospitalizations, and the nutritional status of individuals with asthma and cystic fibrosis.
- 1 January 2024
- Published by FapUNIFESP (SciELO) in Revista Paulista de Pediatria
- Vol. 42, e2024111
Open AccessTelehealth for children and adolescents with chronic pulmonary disease: systematic review
To revise the impact of telehealth on the quality of life, reduction in pulmonary exacerbations, number of days using antibiotics, adherence to treatment, pulmonary function, emergency visits, hospitalizations, and the nutritional status of individuals with asthma and cystic fibrosis.
- Open Access
- 27 October 2023
- Published by Sociedade Brasileira de Pneumologia e Tisiologia in Jornal Brasileiro de Pneumologia
- Vol. 49 (5) , e20230242
Family perception of a telehealth program for people with cystic fibrosis during the COVID-19 pandemic in northeastern Brazil
- 27 October 2023
- Published by Sociedade Brasileira de Pneumologia e Tisiologia in Jornal Brasileiro de Pneumologia
- Vol. 49 (5) , e20230242
Open AccessFamily perception of a telehealth program for people with cystic fibrosis during the COVID-19 pandemic in northeastern Brazil
- Open Access
- 1 January 2023
- Published by FapUNIFESP (SciELO) in Revista Paulista de Pediatria
- Vol. 41, e2022092
Respiratory function of children and adolescents with osteogenesis imperfecta: respiratory muscle strength, forced vital capacity, and peak expiratory flow
Objective: This study aims to evaluate the respiratory function of children and adolescents with osteogenesis imperfecta (OI) followed up at a referral center. Methods: A cross-sectional study was conducted with a non-probabilistic sample. Manovacuometry was performed with the measurement of maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP), and in addition, peak expiratory flow (PEF) and ventilometry were performed to measure forced vital capacity (FVC). Results: In total, 23 individuals were evaluated, with a mean age of 11.6±3.4 years, 56.5% of whom were females. Regarding the classification of OI, 56.5% of the sample belonged to type IV, 30.5% to type III, and 13% to type I. The mean MIP was 64.4% of the predicted, and the mean MEP was 56.2% of the predicted. Overall, the mean PEF was 213.9 L/min, but only 140.6 L/min in the OI type III group. Median FVC was 1.9 L, corresponding to 110% of the predicted. Conclusions: Respiratory function of the study subjects was altered, with respiratory muscle strength values lower than expected in the whole sample, and peak expiratory flow was significantly reduced in the OI type III group.
- 1 January 2023
- Published by FapUNIFESP (SciELO) in Revista Paulista de Pediatria
- Vol. 41, e2022092
Open AccessRespiratory function of children and adolescents with osteogenesis imperfecta: respiratory muscle strength, forced vital capacity, and peak expiratory flow
Objective: This study aims to evaluate the respiratory function of children and adolescents with osteogenesis imperfecta (OI) followed up at a referral center. Methods: A cross-sectional study was conducted with a non-probabilistic sample. Manovacuometry was performed with the measurement of maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP), and in addition, peak expiratory flow (PEF) and ventilometry were performed to measure forced vital capacity (FVC). Results: In total, 23 individuals were evaluated, with a mean age of 11.6±3.4 years, 56.5% of whom were females. Regarding the classification of OI, 56.5% of the sample belonged to type IV, 30.5% to type III, and 13% to type I. The mean MIP was 64.4% of the predicted, and the mean MEP was 56.2% of the predicted. Overall, the mean PEF was 213.9 L/min, but only 140.6 L/min in the OI type III group. Median FVC was 1.9 L, corresponding to 110% of the predicted. Conclusions: Respiratory function of the study subjects was altered, with respiratory muscle strength values lower than expected in the whole sample, and peak expiratory flow was significantly reduced in the OI type III group.
- Open Access
- 5 August 2022
- Published by Elsevier in Jornal de Pediatria
- Vol. 99 (1) , 94-98
Functional status of individuals with osteogenesis imperfecta: data from a reference center
- 5 August 2022
- Published by Elsevier in Jornal de Pediatria
- Vol. 99 (1) , 94-98
Open AccessFunctional status of individuals with osteogenesis imperfecta: data from a reference center
- Open Access
- 1 January 2022
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 114, 128-131
Detection and sequencing of Zika virus in normocephalic newborns with congenital Zika infection
- 1 January 2022
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 114, 128-131
Open AccessDetection and sequencing of Zika virus in normocephalic newborns with congenital Zika infection
- Open Access
- 5 July 2019
- Published by BMJ in BMJ Paediatrics Open
- Vol. 3 (1) , e000486
Neurodevelopmental delay in normocephalic children with in utero exposure to Zika virus
Neurodevelopment in 29 normocephalic children with in utero exposure to Zika virus (ZIKV) was evaluated by the Bayley Scales of Infant and Toddler Development-Third Edition. Ten (35%) infants presented neurodevelopment delay. Language, cognitive and motor delays were identified in 9 (31%), 4 (14%) and 1 (3%) infants, respectively. Children exposed to ZIKV in utero must undergo careful evaluations for the early detection of any neurodevelopment delays in order to implement prompt intervention.
- 5 July 2019
- Published by BMJ in BMJ Paediatrics Open
- Vol. 3 (1) , e000486
Open AccessNeurodevelopmental delay in normocephalic children with in utero exposure to Zika virus
Neurodevelopment in 29 normocephalic children with in utero exposure to Zika virus (ZIKV) was evaluated by the Bayley Scales of Infant and Toddler Development-Third Edition. Ten (35%) infants presented neurodevelopment delay. Language, cognitive and motor delays were identified in 9 (31%), 4 (14%) and 1 (3%) infants, respectively. Children exposed to ZIKV in utero must undergo careful evaluations for the early detection of any neurodevelopment delays in order to implement prompt intervention.